NeuroPace (NASDAQ:NPCE) Price Target Raised to $22.00

NeuroPace (NASDAQ:NPCE) had its target price lifted by UBS Group from $18.00 to $22.00 in a research note released on Tuesday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock.

NPCE has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroPace in a research report on Tuesday, December 9th. Leerink Partners reaffirmed an “outperform” rating and issued a $19.00 price objective on shares of NeuroPace in a research note on Wednesday, November 5th. Wells Fargo & Company increased their price objective on shares of NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. increased their price objective on shares of NeuroPace from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price target on shares of NeuroPace in a report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.50.

NeuroPace Stock Up 0.8%

NPCE stock opened at $15.74 on Tuesday. The company has a quick ratio of 3.94, a current ratio of 4.86 and a debt-to-equity ratio of 3.17. The business has a 50 day moving average of $13.39 and a 200 day moving average of $11.19. NeuroPace has a twelve month low of $7.56 and a twelve month high of $18.98. The firm has a market cap of $524.30 million, a PE ratio of -20.71 and a beta of 1.85.

NeuroPace (NASDAQ:NPCE) last released its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. NeuroPace had a negative return on equity of 136.60% and a negative net margin of 25.28%.The firm had revenue of $27.35 million for the quarter, compared to analysts’ expectations of $24.64 million. On average, research analysts forecast that NeuroPace will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

A number of hedge funds and other institutional investors have recently bought and sold shares of NPCE. Ameritas Investment Partners Inc. increased its position in NeuroPace by 83.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock valued at $27,000 after buying an additional 1,118 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock valued at $30,000 after purchasing an additional 1,239 shares during the period. Quantbot Technologies LP purchased a new position in shares of NeuroPace during the 2nd quarter valued at approximately $35,000. Quarry LP boosted its stake in shares of NeuroPace by 94.9% in the third quarter. Quarry LP now owns 3,845 shares of the company’s stock worth $40,000 after acquiring an additional 1,872 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its position in NeuroPace by 72.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company’s stock worth $71,000 after purchasing an additional 2,668 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.